Buy high-purity KLOW80 stack in Australia (BPC-157 10mg + GHK-Cu 50mg + TB-500 10mg + KPV 10mg, 80mg total). Third-party lab tested at >99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.
What is KLOW80? KLOW80 takes the three-peptide GLOW70 blend and adds KPV, giving one vial that covers four repair and inflammation pathways at once — BPC-157, the copper peptide GHK-Cu, TB-500 and the α-MSH fragment KPV. Laboratories use it to study angiogenesis, collagen synthesis, cell migration and NF-κB-linked inflammation together across wound, skin and gut models. Optic Labs supplies HPLC-tested KLOW80 (>99% purity for each peptide) as a co-lyophilised 80mg vial for laboratory research use only, dispatched Australia-wide from Sydney.
About the KLOW80 stack
KLOW80 is a four-compound research stack co-lyophilised in a single vial: 10mg BPC-157 (a pentadecapeptide derived from gastric juice protein BPC), 50mg GHK-Cu (a copper-binding tripeptide), 10mg TB-500 (a 17-amino-acid fragment of thymosin β-4), and 10mg KPV (an α-MSH-derived tripeptide, Lys-Pro-Val). KLOW80 extends the GLOW70 stack with KPV's anti-inflammatory and gut-barrier research profile, giving researchers a single working unit that spans angiogenic, copper-dependent collagen-synthesis, actin-remodelling and α-MSH-pathway tools. It is a frequent choice in animal-model and cell-culture research where investigators want broad coverage of repair and inflammatory pathways in parallel.
Optic Labs supplies KLOW80 in Australia as a co-lyophilised powder, 80mg total, third-party HPLC verified at >99% purity for each constituent peptide. The stack is supplied strictly for laboratory research use only and is not intended for human consumption, clinical, cosmetic, diagnostic or veterinary application.
Product specifications
-
Compound: BPC-157 (10mg) + GHK-Cu (50mg) + TB-500 (10mg) + KPV (10mg) co-lyophilised stack
-
BPC-157: CAS 137525-51-0, ~1419.5 g/mol, pentadecapeptide
-
GHK-Cu: CAS 49557-75-7 (peptide) / 89030-95-5 (copper-bound), ~340.4 g/mol (free peptide), Gly-His-Lys with Cu2+
-
TB-500: CAS 77591-33-4, 17-amino-acid fragment of thymosin β-4
-
KPV: CAS 67727-97-3, ~342.4 g/mol, Lys-Pro-Val tripeptide derived from α-MSH(11–13)
-
Form: Lyophilised powder (co-formulated)
-
Purity: >99% by HPLC for each peptide
-
Available size: 80mg total per vial (10mg BPC-157 + 50mg GHK-Cu + 10mg TB-500 + 10mg KPV)
-
Storage: 2–8°C, protect from light. Reconstituted: 2–8°C, used within 30 days.
-
Origin: Manufactured to research-grade specifications, third-party HPLC verified
-
Shipping: Australia-wide domestic dispatch from Sydney, NSW
Research background
The four peptides in KLOW80 cover overlapping but distinct repair and inflammatory pathways. BPC-157 is characterised in published research for angiogenic, nitric-oxide and growth-factor signalling; GHK-Cu for copper-dependent collagen synthesis and gene-expression modulation; TB-500 for actin sequestration and cell migration; KPV for α-MSH-pathway anti-inflammatory effects and gut-barrier research. Combining them allows investigators to probe parallel pathway engagement in connective-tissue, dermal, gastrointestinal and inflammation models within a single working unit.
- BPC-157: tendon, ligament and gastrointestinal injury models examining VEGF/eNOS signalling and fibroblast outgrowth.
- GHK-Cu: collagen and elastin synthesis research in dermal fibroblasts and ex-vivo skin models.
- GHK-Cu: gene-expression studies modulating antioxidant, anti-inflammatory and tissue-remodelling pathways.
- TB-500: G-actin sequestration and actin-cytoskeleton remodelling research relevant to cell migration.
- TB-500: cardiac, dermal, corneal and hair-follicle research examining endothelial and keratinocyte migration.
- KPV: α-MSH-derived tripeptide research on NF-κB modulation and pro-inflammatory cytokine attenuation in cell-culture and rodent colitis models.
- Combined-peptide protocols in models combining inflammatory and repair endpoints, where multi-pathway coverage is the design objective.
For deeper background, see our BPC-157 complete research guide, our GHK-Cu copper peptide guide, our TB-500 research guide and our KPV anti-inflammatory research guide. Researchers working with reconstitution should also reference our peptide reconstitution guide.
Reconstitution and handling
KLOW80 is co-lyophilised — all four peptides dissolve together when the vial is reconstituted. Use sterile bacteriostatic water. Adding 4mL of bacteriostatic water to an 80mg vial yields 20mg/mL total peptide, which corresponds to 2.5mg/mL BPC-157, 12.5mg/mL GHK-Cu, 2.5mg/mL TB-500 and 2.5mg/mL KPV. A 5mL reconstitution gives 16mg/mL total (2mg/mL BPC-157, 10mg/mL GHK-Cu, 2mg/mL TB-500, 2mg/mL KPV). Add diluent slowly down the side of the vial — do not inject directly onto the lyophilised cake — and allow the powder to dissolve without vigorous shaking. Reconstituted KLOW80 should be stored at 2–8°C, protected from light, and used within 30 days. For dilution maths for any working volume, see our peptide reconstitution calculator guide and our peptide storage guide.
Commonly stacked research peptides
Researchers using KLOW80 commonly hold its constituent peptides separately for protocols requiring different ratios or single-compound arms:
-
BPC-157 — single-compound vial for protocols at non-stack ratios.
-
GHK-Cu — single-compound copper-peptide vial.
-
TB-500 — single-compound thymosin β-4 fragment vial.
-
KPV — single-compound α-MSH-derived tripeptide for anti-inflammatory and gut-barrier research.
-
GLOW70 stack — three-compound version of KLOW80 without the KPV arm.
For broader stack-design context, see our peptide research stacks overview.
Frequently asked questions
Is KLOW80 legal in Australia?
None of the constituent peptides — BPC-157, GHK-Cu, TB-500 or KPV — is an approved therapeutic good in Australia, and none is registered with the Therapeutic Goods Administration (TGA). Optic Labs supplies KLOW80 strictly for laboratory research, development and analytical use — not for human consumption, clinical or cosmetic application. For a detailed overview of how research peptides sit within the Australian regulatory framework, see our guide to peptide legality and TGA compliance in Australia.
What is KLOW80?
KLOW80 is a co-lyophilised four-compound research stack containing 10mg BPC-157, 50mg GHK-Cu, 10mg TB-500 and 10mg KPV in a single vial. The four peptides are co-studied in repair, dermal, gastrointestinal and inflammation research. For background on each, see our BPC-157, GHK-Cu, TB-500 and KPV guides.
How does KLOW80 differ from GLOW70?
KLOW80 is essentially the GLOW70 stack with an additional 10mg of KPV added to the same vial. Researchers who want anti-inflammatory and gut-barrier pathway coverage alongside the angiogenic, copper-dependent collagen-synthesis and actin-remodelling tools of GLOW70 typically reach for KLOW80; researchers running designs without an inflammation arm typically use GLOW70 instead.
How much bacteriostatic water do I mix with a KLOW80 vial?
For an 80mg vial, 4mL of bacteriostatic water yields 20mg/mL total peptide (2.5mg/mL BPC-157, 12.5mg/mL GHK-Cu, 2.5mg/mL TB-500, 2.5mg/mL KPV). 5mL gives 16mg/mL total. See our reconstitution calculator guide for worked examples at other volumes.
How should reconstituted KLOW80 be stored?
Reconstituted KLOW80 should be stored at 2–8°C, protected from light, and used within 30 days. Lyophilised vials are stable at 2–8°C until reconstitution. For full handling guidance, see our peptide storage research guide.
Where does Optic Labs ship to?
Optic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.
Legal disclaimer
All products on this site are supplied for laboratory research, development or analytical use only. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the Therapeutic Goods Administration (TGA) or the APVMA and are not intended to diagnose, treat, cure or prevent any disease. Optic Labs is not a compounding pharmacy or manufacturing facility as defined under the Therapeutic Goods Act 1989, and is not a registered provider of scheduled medicines or therapeutic goods.
